- Home
- ADUS vs ADPT Comparison
ADUS vs ADPT Comparison
Compare ADUS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUS
- ADPT
- Stock Information
- Founded
- ADUS 1979
- ADPT 2009
- Country
- ADUS United States
- ADPT United States
- Employees
- ADUS N/A
- ADPT N/A
- Industry
- ADUS Medical/Nursing Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADUS Health Care
- ADPT Health Care
- Exchange
- ADUS Nasdaq
- ADPT Nasdaq
- Market Cap
- ADUS 2.1B
- ADPT 1.8B
- IPO Year
- ADUS 2009
- ADPT 2019
- Fundamental
- Price
- ADUS $110.27
- ADPT $12.61
- Analyst Decision
- ADUS Buy
- ADPT Strong Buy
- Analyst Count
- ADUS 12
- ADPT 8
- Target Price
- ADUS $140.58
- ADPT $12.38
- AVG Volume (30 Days)
- ADUS 122.8K
- ADPT 1.8M
- Earning Date
- ADUS 11-03-2025
- ADPT 11-06-2025
- Dividend Yield
- ADUS N/A
- ADPT N/A
- EPS Growth
- ADUS 7.74
- ADPT N/A
- EPS
- ADUS 4.52
- ADPT N/A
- Revenue
- ADUS $1,274,082,000.00
- ADPT $205,216,000.00
- Revenue This Year
- ADUS $24.29
- ADPT $32.76
- Revenue Next Year
- ADUS $6.83
- ADPT $15.81
- P/E Ratio
- ADUS $24.84
- ADPT N/A
- Revenue Growth
- ADUS 14.29
- ADPT 21.60
- 52 Week Low
- ADUS $88.96
- ADPT $3.98
- 52 Week High
- ADUS $136.72
- ADPT $13.68
- Technical
- Relative Strength Index (RSI)
- ADUS 43.91
- ADPT 51.14
- Support Level
- ADUS $110.05
- ADPT $12.34
- Resistance Level
- ADUS $115.82
- ADPT $13.68
- Average True Range (ATR)
- ADUS 2.87
- ADPT 0.56
- MACD
- ADUS -0.61
- ADPT -0.08
- Stochastic Oscillator
- ADUS 2.55
- ADPT 20.15
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, mainly to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are medical in nature to those individuals who may require assistance during an illness or after surgery.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).